<DOC>
	<DOC>NCT00917306</DOC>
	<brief_summary>The open label study is designed to assess the safety and efficacy of 0.05% PEP005 Gel when applied to an area of skin containing 4-8 AK lesions on non-head locations.</brief_summary>
	<brief_title>A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis, Actinic</mesh_term>
	<criteria>Patient is male or female and at least 18 years of age. Female patient must be of either: Nonchildbearing potential, postmenopausal, or there is a confirmed clinical history of sterility (e.g., the patient is without a uterus) Childbearing potential, provided there are negative urine pregnancy test results prior to study treatment, to rule out pregnancy Exclusion Criteria Cosmetic or therapeutic procedures within two weeks and within 2 cm of the selected treatment area. Treatment with immunomodulators, interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks. Treatment with 5FU, imiquimod, diclofenac, or photodynamic therapy: within 8 weeks and 2 cm of the selected treatment area.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Peplin</keyword>
	<keyword>Actinic keratosis</keyword>
	<keyword>PEP005</keyword>
</DOC>